<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01934725</url>
  </required_header>
  <id_info>
    <org_study_id>SECRETO</org_study_id>
    <nct_id>NCT01934725</nct_id>
  </id_info>
  <brief_title>Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome</brief_title>
  <acronym>SECRETO</acronym>
  <official_title>Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome (SECRETO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SECRETO Study Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Finnish Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academy of Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>SECRETO Study Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND: In industrialized countries a considerable and increasing proportion of strokes
      occur at younger ages. Stroke at young age causes marked disability at worst and thus
      long-standing socioeconomic consequences and exposes survivors for 4-fold risk of premature
      death compared with background population. Up to 50% of young patients with ischemic stroke
      remain without definitive etiology for their disease despite extensive modern diagnostic
      work-up (i.e. cryptogenic stroke). The group of cryptogenic strokes includes those with
      patent foramen ovale (PFO) or other abnormalities in the atrial septum in the heart as the
      only or concomitant finding. Population prevalence of PFO is high, 25%, and the mechanisms
      how PFO would be associated causally with ischemic stroke remain to be clarified. Moreover,
      there are only scarce data on clinical outcome, long-term risk of new vascular events, and
      prevention of such events in these patients.

      DESIGN: Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the
      Etiology, Triggers, and Outcome (SECRETO) is an international prospective multicenter
      case-control study of young adults (age 18-49) presenting with an imaging-positive first-ever
      ischemic stroke of undetermined etiology (aim N=2000). Patients are included after
      standardized diagnostic procedures (brain MRI, imaging of intracranial and extracranial
      vessels, cardiac imaging, and screening for coagulopathies) and age- and sex-matched to
      healthy controls in a 1:1 fashion. Up to 45 study sites worldwide will be needed to recruit
      the planned participant population during a 3-year period. Neurovascular imaging and
      echocardiography studies, and ECGs will be read centrally.

      AIMS: SECRETO involves five principal fields of investigation: (1) Stroke triggers and
      clinical risk factors; (2) Long-term prognosis (new vascular events, functional and
      psychosocial outcomes); (3) Abnormalities of thrombosis and hemostasis; (4) Biomarkers of
      e.g. inflammation, atherogenesis, endothelial function, thrombosis, platelet activation, and
      hemodynamic stress to characterize postulated cryptogenic stroke mechanisms; and (5) genetic
      study, including genome-wide association and candidate gene studies as well as
      next-generation sequencing approach. All analyses consider cardiac functional and interatrial
      structural properties as a possible mediator. Furthermore, SECRETO Family Study (substudy)
      aims at collecting extensive family history of thrombotic events from informative patients
      being screened for SECRETO main study and collect genetic samples from all consenting family
      members for whole-genome sequencing.

      SIGNIFICANCE: SECRETO will provide novel information on clinical and subclinical risk
      factors, both transient and chronic, predisposing to cryptogenic ischemic stroke in young
      adults. This study also reveals long-term prognosis of this understudied patient population
      and may discover new genetic background underlying the disease mechanism and provide
      potential targets for drug development.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Nonfatal or fatal recurrent ischemic cerebrovascular event</measure>
    <time_frame>10 years</time_frame>
    <description>Ischemic stroke or transient ischemic attack</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of noncerebrovascular arterial or venous thrombotic events, or cerebral venous thrombosis</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death from any cause</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New-onset atrial fibrillation</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Modified Rankin Scale</measure>
    <time_frame>10 years</time_frame>
    <description>Functional outcome will be assessed with modified Rankin Scale at mandatory 3-month visit and at annual follow-up contacts from year 1 to year 10.</description>
  </other_outcome>
  <other_outcome>
    <measure>Vocational outcome</measure>
    <time_frame>10 years</time_frame>
    <description>Vocational status will be assessed at each follow-up contact with Poststroke Working Activity Questionnaire and a set of questions designed for the study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cognitive outcome</measure>
    <time_frame>3 months</time_frame>
    <description>Cognition will be assessed at mandatory 3-month follow-up visit (Montreal Cognitive Assessment).</description>
  </other_outcome>
  <other_outcome>
    <measure>Anxiety and depression</measure>
    <time_frame>10 years</time_frame>
    <description>Poststroke anxiety and depression will be evaluated at 3-month visit, 1-year, 5-year, and 10-year follow-up contacts with Hospital Anxiety and Depression Scale.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>10 years</time_frame>
    <description>Quality of life will be assessed at 3-month visit, 1-year, 5-year, and 10-year follow-up contacts with EuroQol questionnaire.</description>
  </other_outcome>
  <other_outcome>
    <measure>Caregiver burden</measure>
    <time_frame>3 months</time_frame>
    <description>Poststroke burden to caregiver will be assessed at 3-month visit with Expanded Caregiver Strain Index Questionnaire.</description>
  </other_outcome>
  <other_outcome>
    <measure>Barthel Index</measure>
    <time_frame>10 years</time_frame>
    <description>Functional outcome will be assessed with Barthel Index at mandatory 3-month visit and at annual follow-up contacts from year 1 to year 10.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Brain Infarction</condition>
  <condition>Ischemic Stroke</condition>
  <condition>Thrombosis</condition>
  <condition>Foramen Ovale, Patent</condition>
  <arm_group>
    <arm_group_label>Patients w/ cryptogenic ischemic stroke</arm_group_label>
    <description>Patients aged 15 to 49 years with unexplained first-ever ischemic stroke</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stroke-free control subjects</arm_group_label>
    <description>Stroke-free subjects age- and gender-matched to patients</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Patients at baseline:

      4 x 2.7 mL sodium citrate tube, aliquoted in 10 x 300 µL cryovials; 1 x 5 mL PPACK sodium
      citrate tube, aliquoted in 5 x 300 µL cryovials; 1 x 8 mL serum tube, aliquoted in 5 x 300 µL
      cryovials; 1 x 9 mL EDTA tube #1, aliquoted in 10 x 300 µL cryovials; 1 x 9 mL EDTA tube #2,
      full blood for DNA extraction.

      Patients at 3-month visit (fasting): 4 x 2.7 mL sodium citrate tube, aliquoted in 10 x 300 µL
      cryovials; 1 x 5 mL PPACK sodium citrate tube, aliquoted in 5 x 300 µL cryovials; 1 x 8 mL
      serum tube, aliquoted in 5 x 300 µL cryovials; 1 x 9 mL EDTA tube, aliquoted in 10 x 300 µL
      cryovials.

      Control subjects:

      4 x 2.7 mL sodium citrate tube, aliquoted in 10 x 300 µL cryovials; 1 x 5 mL PPACK sodium
      citrate tube, aliquoted in 5 x 300 µL cryovials; 1 x 8 mL serum tube, aliquoted in 5 x 300 µL
      cryovials; 1 x 9 mL EDTA tube #1, aliquoted in 10 x 300 µL cryovials; 1 x 9 mL EDTA tube #2,
      full blood for DNA extraction.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. Patients aged 18 to 49 hospitalized due to first-ever imaging-positive ischemic stroke
             of undetermined etiology;

          2. Age-, gender- and race-ethnicity-matched stroke-free control subjects
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        PATIENTS:

        Inclusion Criteria:

          1. Age 18 to 49 at stroke onset

          2. Patient hospitalized due to first-ever imaging-positive ischemic stroke of
             undetermined etiology after complete timely diagnostic testing.

        Exclusion Criteria:

          1. Baseline mandatory tests not obtained in the first week following stroke onset,
             including:

               -  Brain MRI

               -  Routine blood tests, including complete blood count, CRP, fasting glucose,
                  creatinine, aPTT, INR, total cholesterol, LDL-cholesterol, HDL-cholesterol,
                  HbA1C, hemoglobin electrophoresis in individuals of African origin

          2. Other baseline mandatory tests not obtained within the first two weeks following
             stroke onset, including:

               -  Imaging of cervicocephalic arteries by CTA, MRA, or DSA

               -  Transesophageal (highly recommended) or transthoracic echocardiography

               -  24-hour Holter monitoring or continuous in-hospital ECG monitoring with automated
                  arrhythmia detection for at least 24 hours

               -  Screening for thrombophilia, including antiphospholipid antibodies and other
                  coagulopathies (any abnormal finding must be retested at mandatory 3-month
                  follow-up visit &gt;12 weeks from initial testing or &gt;4 weeks after cessation of
                  anticoagulation at any later time point); mandatory tests include anticardiolipin
                  antibodies, lupus anticoagulant, anti-β2-glycoprotein antibodies, factor V
                  mutation (or aPC resistency ruled out), factor II mutation, homocysteine,
                  antithrombin III, protein C, and protein S

          3. No evidence of current brain ischemia

          4. Current stroke due to cerebral venous thrombosis or as a complication of subarachnoid
             hemorrhage, angiography, or cardiac surgery

          5. Patient otherwise not eligible for the study or adherent for follow-up (eg
             nonresident) or has concurrent disease affecting outcome (eg multiple sclerosis,
             cancer)

          6. Informed consent not obtained from the patient or a proxy.

        CONTROL SUBJECTS:

        Inclusion Criteria:

          1. Age 18 to 49 years

          2. Absence of prior ischemic stroke as ascertained using the Questionnaire for Verifying
             Stroke-Free Status

        Exclusion Criterion:

        1. Informed consent not obtained
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jukka Putaala, A/Prof., MD, PhD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sylvain Lanthier, Prof., MD, OD, CSPQ</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUM - Hôpital Notre-Dame</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Kittner, Prof., MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jukka Putaala, A/Prof., MD, PhD, MSc</last_name>
    <phone>+35894711</phone>
    <email>jukka.putaala@hus.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Turgut Tatlisumak, Prof., MD, PhD</last_name>
    <phone>+35894711</phone>
    <email>Turgut.Tatlisumak@neuro.gu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHUM - Hôpital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvain Lanthier, MD, OD, CSPQ</last_name>
      <email>sylanthier@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sylvain Lanthier, MD, OD, CSPQ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janika Kõrv, MD, PhD</last_name>
      <email>Janika.Korv@kliinikum.ee</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>FI-00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jukka Putaala, MD, PhD, MSc</last_name>
      <phone>+35894711</phone>
      <email>jukka.putaala@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Sami Curtze, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Strbian, MD, PhD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Gordin, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mika Lehto, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juha Sinisalo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lauri Soinne, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tiina Sairanen, MD, PhD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Terttu Heikinheimo-Connell, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Satu Mustanoja, MD, PhD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jukka Putaala, MD, PhD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Per-Henrik Groop, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Martinez-Majander, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reetta Kivioja, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <zip>70029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pekka Jäkälä, MD, PhD</last_name>
      <email>pekka.jakala@kuh.fi</email>
    </contact>
    <investigator>
      <last_name>Ossi Nerg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marja Hedman, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pekka Jäkälä, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juha Huhtakangas, MD, PhD</last_name>
      <email>juha.huhtakangas@ppshp.fi</email>
    </contact>
    <investigator>
      <last_name>Ulla Junttola, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antti Hakalahti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juha Huhtakangas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heikki Numminen, MD, PhD</last_name>
      <email>heikki.numminen@pshp.fi</email>
    </contact>
    <contact_backup>
      <last_name>Juho Tynkkynen, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Marko Virtanen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Essi Ryödi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heikki Numminen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Turku University Central Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauli Ylikotila, MD, PhD</last_name>
      <email>pauli.ylikotila@tyks.fi</email>
    </contact>
    <contact_backup>
      <last_name>Risto O. Roine, Prof.</last_name>
      <email>risto.roine@tyks.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Riikka Lautamäki, A/Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antti Saraste, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pauli Ylikotila, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Risto O. Roine, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Giessen</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tanislav Christian, MD</last_name>
      <email>Christian.Tanislav@neuro.med.uni-giessen.de</email>
    </contact>
    <investigator>
      <last_name>Christian Tanislav, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ernst-Moritz-Arndt University Medicine</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bettina von Sarnowski, MD, PhD</last_name>
      <email>bvsarnow@uni-greifswald.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Ludwigshafen a. Rh.</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Armin J Grau, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Frederick Palm, MD, PhD</last_name>
      <email>PALMF@klilu.de</email>
    </contact_backup>
    <investigator>
      <last_name>Armin J Grau, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederick Palm, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>&quot;Attikon&quot; Hospital, University of Athens, School of Medicine</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgios Tsivgoulis, MD, PhD</last_name>
      <email>tsivgoulisgiorg@yahoo.gr</email>
    </contact>
    <investigator>
      <last_name>Georgios Papadimitropoulos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georgios Tsivgoulis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Pezzini, MD, PhD</last_name>
      <email>ale_pezzini@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Alessandro Pezzini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marialuisa Zedde, MD, PhD</last_name>
      <email>Marialuisa.Zedde@asmn.re.it</email>
    </contact>
    <investigator>
      <last_name>Marialuisa Zedde, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santariskiu klinikos</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dalius Jatuzis, Prof.</last_name>
      <email>Dalius.Jatuzis@santa.lt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frank-Erik de Leeuw, MD, PhD</last_name>
      <email>FrankErik.deLeeuw@radboudumc.nl</email>
    </contact>
    <investigator>
      <last_name>Frank-Erik de Leeuw, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Waje-Andreassen, Prof.</last_name>
      <email>uwan@helse-bergen.no</email>
    </contact>
    <investigator>
      <last_name>Halvor Naess, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anette Fromm, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sahrai Saeed, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulrike Waje-Andreassen, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva Gerdts, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catarina A. Fonseca, MD, PhD, MPH</last_name>
      <email>catarinagfonseca@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>José M. Ferro, MD, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Catarina A. Fonseca, MD, PhD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabel Amorim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Almeida, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Paz University Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patricia Martinez-Sanchez, MD</last_name>
      <email>patrindalo@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Turgut Tatlisumak, Prof.</last_name>
      <email>Turgut.Tatlisumak@neuro.gu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul University Istanbul Faculty of Medecine</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nilufer Yesilot Barlas, MD, PhD</last_name>
      <email>niluferyes@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ali Elitok, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nilufer Yesilot Barlas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Esme Ekizoglu Turgut, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Switzerland</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.secretostudy.net</url>
    <description>Study website</description>
  </link>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2013</study_first_submitted>
  <study_first_submitted_qc>August 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2013</study_first_posted>
  <last_update_submitted>November 22, 2016</last_update_submitted>
  <last_update_submitted_qc>November 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>SECRETO Study Consortium</investigator_affiliation>
    <investigator_full_name>Jukka Putaala</investigator_full_name>
    <investigator_title>Associate Prof., MD, PhD, MSc</investigator_title>
  </responsible_party>
  <keyword>Ischemic Stroke</keyword>
  <keyword>Brain Infarction</keyword>
  <keyword>Patent Foramen Ovale</keyword>
  <keyword>Stroke in the Young</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Cerebral Venous Thrombosis</keyword>
  <keyword>Pulmonary Embolism</keyword>
  <keyword>Deep Vein Thrombosis</keyword>
  <keyword>Subarachnoid Hemorrhage</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Databases, Genetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Brain Infarction</mesh_term>
    <mesh_term>Foramen Ovale, Patent</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

